Pharmaceuticals firm Divi's Laboratories on Saturday said it has received a draft assessment order from the Income Tax Department proposing additions and disallowances of ₹570.51 crore to its returned income for FY2022-23 (assessment year 2023-24). The proposed additions relate to transfer pricing adjustments on specified domestic transactions and corporate tax adjustments.